USP Silenced Model

SilenciX® is a unique syngenic cellular model based on a new siRNA delivery system,  which brings researchers an exceptional opportunity to rapidly screen and analyse new therapeutics in the early stages of development.

As USPs are a family of deubiquinating enzymes involved in many cancer-associated pathways, USP-SilenciX® helps researchers decipher this attractive field.

SilenciX®, silenced model promising for

Ready-to-dispatch USPKD SilenciX cell lines

Designation % of KD*  Cat nr
 USP7 HeLa SilenciX®       74%       01-00159
 USP9X HeLa SilenciX®       73%       01-00160
 USP14 HeLa SilenciX®       79%       01-00163
 USP19 HeLa SilenciX®       71%       01-00164

* tebu-bio quality controls are performed by qPCR

Would you like to be informed in real time on the release of our new USP SilenciX®? Just let us know.

More than 100 target-specific HeLa SilenciX® are already for Ubiquitin Proteasome Pathways, DNA Repair proteins, Hypoxia...

Keep checking our expanding list!

Easy silenced model to use

Just thaw the cells and start your tests!

Recently, Brem at al. have shown, by using the MMR-defective SilenciX HeLa-MSH2 cell line (cat nr 01-00023), that 6-Thioguanin (6-TG) treatment activates the Fanconi Anemia pathway in human cells. This activation is partly independent of MMR-mediated processing of DNA 6-TG since WB have revealed that 6-TG induced FANCD2 monoubiquitination (a sensitive indicator of FA pathway activation) in both MMR-proficient and -defective cells.